

---

## Bayer Expands Radiology Business into AI Market with Calantic™ Digital Solutions



- 
- AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity
  - Cloud-hosted platform provides access to AI applications\* that integrate into standard medical imaging workflow
  - Market introduction to start in US and several European countries
  - Strategically complements Bayer's comprehensive portfolio of contrast media, fluid delivery systems and digital management solutions
- 

Bayer announced the launch of Calantic™ Digital Solutions, a new platform delivering access to digital applications, including artificial intelligence (AI) enabled programs for medical imaging. The offering contains tools which aid radiologists and their teams to improve prioritization, lesion detection, quantification, and productivity. By providing access to AI radiology applications through the Calantic Digital Solutions platform Bayer will expand its comprehensive portfolio beyond contrast media, medical devices, software and services. The new platform will support healthcare professionals at all stages of their work, from diagnosis through treatment of their patients.

"AI has the potential to transform healthcare, and particularly in medical imaging it can turn the growing amounts of data into value-adding insights to support radiologists and their teams in their decision-making", said Dr. Ryan Lee, Chair, Department of Radiology, Einstein Healthcare Network, Philadelphia, USA. "It is crucial to drive innovation in this area and broaden access to digital tools that can help address the rising demand for solutions which improve the speed and accuracy of diagnoses."

"As a leader in key Radiology areas and building on our deep medical understanding across a multitude of diagnostic and therapeutic areas, Calantic Digital Solutions underlines our commitment to continue accelerating innovation for the benefit of patients and their physicians", said Gerd Krueger, Head of Radiology, Bayer Pharmaceuticals. "With Calantic Digital Solutions, we are entering the fastest growing segment in the radiology market and taking the next step on our way from a product provider to a solution provider, following our mission to provide an ecosystem of third-party and Bayer products to deliver state-of-the art disease-oriented solutions for radiologists and their teams."

Calantic Digital Solutions is a suite of digital radiology AI-enabled applications which assist radiologists and their teams at critical steps within a patient's treatment journey. The vendor-neutral, cloud-hosted platform includes a growing number of applications designed to aid in prioritization, lesion detection and quantification, as well as apps that automate routine tasks and measurements, improve the radiology suites' workflow, and free up time for radiologists and their teams. The offering is orchestrated by body region and procedure, initially focusing on thoracic and neurological diseases, such as pulmonary nodule detection and triage of potential intracerebral hemorrhage (ICH) and large vessel occlusions (LVO). ICH and LVO can be associated with stroke. More disease-specific application packages will be added moving forward. Bayer provides services around installation, configuration, and training of the platform and its applications. First launch markets will include the US and several European countries, with more regions to follow, upon local regulatory approvals as applicable.

**Source:** [Bayer](#)

Published on : Tue, 28 Jun 2022